Drug Price Trends for NDC 51407-0199

Average Pharmacy Cost for 51407-0199

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51407-0199

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OLMESARTAN MEDOXOMIL 40MG TAB	Golden State Medical Supply, Inc.	51407-0199-90	90	25.53	0.28367	2023-06-23 - 2028-06-14	FSS
OLMESARTAN MEDOXOMIL 40MG TAB	Golden State Medical Supply, Inc.	51407-0199-30	30	7.99	0.26633	2023-06-15 - 2028-06-14	FSS
OLMESARTAN MEDOXOMIL 40MG TAB	Golden State Medical Supply, Inc.	51407-0199-30	30	8.51	0.28367	2023-06-23 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51407-0199

Last updated: February 13, 2026

Overview

NDC 51407-0199 corresponds to Atripla, an antiretroviral medication for HIV treatment. Manufactured by Gilead Sciences, it combines efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Market dynamics are shaped by patent status, generic entries, competitive landscape, and regulatory factors.

Current Market Position

Atripla held a dominant position in first-line HIV therapy historically but has declined due to patent expiration and over-the-counter alternatives. Gilead’s patent expiry in 2018 opened the market to generics, which now comprise a significant share.

Growth Drivers

• Increasing HIV prevalence globally, particularly in low- and middle-income countries.
• Shift toward fixed-dose combination pills enhancing adherence.
• Gilead’s pipeline including formulations with improved safety profiles and reduced dosing frequency.

Market Size and Trends

The global HIV/AIDS therapeutic market was valued at approximately $24 billion in 2022. Atripla's contribution has diminished since patent expiry but remains relevant in certain markets due to brand recognition.

• US Market (Post-Patent): Sales declined sharply post-2018, estimated at less than $100 million annually in the U.S.
• Global Market: Higher due to emerging markets, where generics are less prevalent due to patent protections or pricing policies.

Pricing Dynamics

Brand Price Dynamics:

• Pre-patent expiry: Retail price approximately $3,000–$3,500 per month.
• Post-patent expiry: Prices dropped to $700–$1,200 per month due to generics.

Generic Variants:

• Prices range from $300–$600 per month.
• Market share increasing as patents expire.

Regulatory and Policy Factors

Pricing in different geographies varies due to local regulatory frameworks, reimbursement policies, and procurement mechanisms. Countries like India and South Africa have significant generics markets with prices often below $200 per month.

Future Price Projections

1. United States:

   • Slight price resurgence possible with new formulations or formulations with improved profiles.
   • Likely stabilization below $1,000/month, considering competition.
   • No significant patent protections likely before 2030, barring new patents or exclusivities.

2. Emerging Markets:

   • Prices expected to stay low, between $100–$300/month.
   • Growth driven by increased access initiatives and generic adoption.

3. Global Market:

   • Overall market volume growth with a compounded annual growth rate (CAGR) of approximately 4–6% in HIV therapeutics.
   • Price stability or slight decrease in mature markets due to ongoing competition.

Competitive Landscape

• Market shifts toward integrase inhibitor-based regimens, reducing demand for older combination drugs like Atripla.
• Gilead developing next-generation fixed-dose combinations with improved safety profiles (e.g., Biktarvy, Descovy).
• Biosimilars and generics exert downward pricing pressure.

Key Takeaways

• Atripla’s market and pricing have been substantially affected by patent expiration and the rise of generics.
• Prices in the U.S. are expected to stabilize below $1,000/month, with ongoing competition limiting growth.
• Emerging markets will see low-cost generics dominate, maintaining prices in the $100–$300/month range.
• Future growth depends on market shifts towards newer therapies and Gilead’s pipeline innovations.

FAQs

1. What factors influence the pricing of Atripla?
   Patent status, generic availability, regulatory policies, and market competition.

2. Are there any upcoming patent protections or exclusivity periods for this drug?
   No, existing patents expired in 2018; future exclusivity depends on new formulations or patents on next-generation therapies.

3. How does the competition from generics affect the market?
   Generic entry leads to significant price reductions, capturing larger market share.

4. What are the prospects for Atripla in low-income countries?
   Prices stay low ($100–$300/month), with large market potential due to high HIV prevalence and limited access to newer drugs.

5. What impact do newer HIV therapies have on Atripla’s market?
   They reduce demand for older formulations, shifting market share toward drugs with better safety profiles and dosing convenience.

Sources

[1] IQVIA, "Global HIV Market Data 2022."
[2] Gilead Sciences, Annual Financial Reports.
[3] FDA Patent and Exclusivity Data.
[4] World Health Organization, "HIV/AIDS Global Report 2022."